A Chemical Genetic Approach to Exploring Novel Therapeutic Space for Colorectal Cancer
探索结直肠癌新治疗空间的化学遗传学方法
基本信息
- 批准号:10600844
- 负责人:
- 金额:$ 13.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-01 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:AnimalsApoptosisBRAF geneBenchmarkingBiological AssayBiologyCancer EtiologyCancer ModelCellsCessation of lifeChemical ModifierChemicalsChemistryClinicalColorectal CancerComplexComputer ModelsDataDevelopmentDiagnosisDiseaseDrosophila genusDrug DesignDrug KineticsEpidermal Growth Factor ReceptorExcretory functionFDA approvedGenesGeneticGenetic ScreeningGoalsHalf-LifeHumanImmunotherapyIn VitroKRAS2 geneLeadLibrariesMalignant NeoplasmsMapsMediatingMetabolismModelingModificationMonomeric GTP-Binding ProteinsMusNatureNeoplasm MetastasisOncogenicPatientsPharmaceutical PreparationsPharmacotherapyPhosphotransferasesPrimary carcinoma of the liver cellsPropertyProtein IsoformsRAF1 geneRefractorySeriesSignal TransductionStructureStructure-Activity RelationshipSurvival RateTP53 geneTestingTherapeuticTherapeutic IndexTimeToxic effectTreatment EfficacyUnited StatesVariantXenograft ModelXenograft procedureabsorptionanalogaurora kinase Achemical geneticscolon cancer cell linecolon cancer patientscomparativecostdesigndrug developmentflygastrointestinalgenetic analysisgenetic approachimprovedin vivoinhibitorinnovationinsightinterdisciplinary approachkinase inhibitormetastatic colorectalmortalitymutantneoplastic cellnetwork attacknovelnovel therapeutic interventionnovel therapeuticspatient derived xenograft modelside effectsmall moleculestructural biologytumortumor growthtumor initiation
项目摘要
Project Summary
Metastatic colorectal cancer (mCRC) is the second leading cause of cancer-related mortality in the United
States, and annually accounts for nearly 500,000 deaths worldwide. Currently, the small molecule kinase
inhibitor (KI) regorafenib is the primary second line therapy for metastatic CRC that is not treatable with
immunotherapy or anti-EGFR therapies. However, regorafenib generally provides only modest improvements in
survival— typically months—and often at the cost of significant side effects. Proposed targets for regorafenib
include kinases that act within tumor cells as well as non-autonomously; however, with over 500 possible targets
in the human kinome, the exact mechanism by which this compound operates remains controversial and not
fully known. This presents a daunting challenge; without a verifiable target or mechanism, no clear path exists
to guide the development of improved therapies for mCRC.
Here, we propose an alternative approach to drug development that focuses on kinase networks in the
context of the whole animal. Specifically, we will take a multidisciplinary approach to define kinases that are
beneficial to inhibit (‘pro-targets’) or avoid (‘anti-targets’) in the context of KRAS-variant CRC. Using Drosophila
and mammalian models, we will identify kinases that—when reduced—alter the efficacy of regorafenib and
similar compounds. We will also conduct extensive structure-activity relationship analyses, evaluating how
modifications in already identified lead compounds impact changes in efficacy and therapeutic index. Finally, we
will use computational structural biology to convert our chemical genetic insights into highly optimized and
precise polypharmacological leads. In this final step, we generate new analogs to selectively eliminate putative
anti-target activity while maintaining or increasing inhibitory activity against other beneficial targets.
We have used our chemical genetic platform to identify a promising lead compound, APS5-86-2, that
demonstrates significant activity relative to regorafenib in several mCRC models, including human patient
derived xenografts (PDX). Comparative analysis suggests that the improved activity of APS5-86-2 relative to
regorafenib derives from distinct polypharmacology on several RTKs and critical cancer drivers, including CDK9,
AURKA, EGFR, BRAF, and RAF1. In this proposal, we examine the mechanism and importance of these and
other putative pro- and anti-target kinases using genetic analysis and in vivo target engagement. The objective
is to identify the kinase networks that mediate KRAS-variant mCRC by combining chemical biology with genetics,
and to then derive inhibitors that best attack these networks through structure-based drug design. We have been
successful previously with a similar approach, but in less complex tumor models (Dar et al., Nature, 2012;
Sonoshita et al., Nature Chem. Bio., 2018); here we seek to extend our platform to a more prevalent disease
with the goal of directly impacting mCRC by creating new, highly differentiated, and improved drugs.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ross Leigh Cagan其他文献
Ross Leigh Cagan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ross Leigh Cagan', 18)}}的其他基金
A Chemical Genetic Approach to Exploring Novel Therapeutic Space for Colorectal Cancer
探索结直肠癌新治疗空间的化学遗传学方法
- 批准号:
10908073 - 财政年份:2023
- 资助金额:
$ 13.86万 - 项目类别:
A Cytochrome P450 Therapeutic Space for Tauopathies
Tau蛋白病的细胞色素 P450 治疗空间
- 批准号:
10461317 - 财政年份:2021
- 资助金额:
$ 13.86万 - 项目类别:
A Chemical Genetic Approach to Exploring Novel Therapeutic Space for Colorectal Cancer
探索结直肠癌新治疗空间的化学遗传学方法
- 批准号:
10359839 - 财政年份:2021
- 资助金额:
$ 13.86万 - 项目类别:
A Chemical Genetic Approach to Exploring Novel Therapeutic Space for Colorectal Cancer
探索结直肠癌新治疗空间的化学遗传学方法
- 批准号:
10182641 - 财政年份:2021
- 资助金额:
$ 13.86万 - 项目类别:
A New Disease Platform Leveraging Complex Drosophila and Mammalian Models
利用复杂果蝇和哺乳动物模型的新疾病平台
- 批准号:
9306960 - 财政年份:2015
- 资助金额:
$ 13.86万 - 项目类别:
A New Disease Platform Leveraging Complex Drosophila and Mammalian Models
利用复杂果蝇和哺乳动物模型的新疾病平台
- 批准号:
9118383 - 财政年份:2015
- 资助金额:
$ 13.86万 - 项目类别:
A Drosophila Model Linking Diet-induced Obesity and Cancer (PQ 1)
将饮食引起的肥胖与癌症联系起来的果蝇模型 (PQ 1)
- 批准号:
8383704 - 财政年份:2012
- 资助金额:
$ 13.86万 - 项目类别:
A Drosophila Model Linking Diet-induced Obesity and Cancer (PQ 1)
将饮食引起的肥胖与癌症联系起来的果蝇模型 (PQ 1)
- 批准号:
8870186 - 财政年份:2012
- 资助金额:
$ 13.86万 - 项目类别:
A Drosophila Model Linking Diet-induced Obesity and Cancer (PQ 1)
将饮食引起的肥胖与癌症联系起来的果蝇模型 (PQ 1)
- 批准号:
8677826 - 财政年份:2012
- 资助金额:
$ 13.86万 - 项目类别:
A Drosophila Model Linking Diet-induced Obesity and Cancer (PQ 1)
将饮食引起的肥胖与癌症联系起来的果蝇模型 (PQ 1)
- 批准号:
8534067 - 财政年份:2012
- 资助金额:
$ 13.86万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
$ 13.86万 - 项目类别:
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
$ 13.86万 - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
$ 13.86万 - 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
$ 13.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
$ 13.86万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
$ 13.86万 - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
$ 13.86万 - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
$ 13.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
$ 13.86万 - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
$ 13.86万 - 项目类别:
Discovery Grants Program - Individual